CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $18.67M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.64: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.65BUSDvs all stocks (USD)
Revenue (TTM)
18.67MUSDvs all stocks (USD)
Beta
0.9440xvs all stocks
52-Week Change
-35.64%vs all stocks
Market Capitalization
2.65BUSDvs all stocks (USD)
Enterprise Value
2.39BUSDvs all stocks (USD)
Forward P/E
-12.78xvs Biotechnology peers
Price to Book (MRQ)
8.18xvs Biotechnology peers
Enterprise to Revenue
128.20xvs Biotechnology peers
Enterprise to EBITDA
-13.09xvs Biotechnology peers
Gross Margin
94.01%vs Biotechnology peers
Operating Margin
-872.23%vs Biotechnology peers
Return on Assets (TTM)
-15.72%vs Biotechnology peers
Return on Equity (TTM)
-157.61%vs Biotechnology peers
Revenue (TTM)
18.67MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2990USDUpdated Sep 28, 2026Quarterly Revenue Growth
11.00%vs Biotechnology peers
Gross Profit (TTM)
-114.71MUSDvs all stocks (USD)
EBITDA (TTM)
-182.92MUSDvs all stocks (USD)
Net Income (TTM)
-252.21MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
11.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-160.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-77.58MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
16.10MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.69MUSDFY2025 · Dec 31, 2025Gross Profit
14.41MUSDFY2025 · Dec 31, 2025Operating Income
-187.83MUSDvs all stocks (USD)
Pre-tax Income
-193.34MUSDFY2025 · Dec 31, 2025Income Tax Expense
5.63MUSDFY2025 · Dec 31, 2025Net Income
-198.97MUSDFY2025 · Dec 31, 2025EBIT
-131.35MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-148.72MUSDFY2025 · Dec 31, 2025Research & Development
140.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.34MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-5.68MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.97MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
61.99MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.46USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.46USDFY2025 · Dec 31, 2025Basic Shares Outstanding
57.50MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
57.50MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-198.97MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-136.55MUSDFY2025 · Dec 31, 2025Free Cash Flow
-136.99MUSDDerived from operating cash flow minus capital expenditure. This filing charges 14.76M of depreciation against 439K of capital expenditure, and its own free-cash-flow line reads -178.4M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
81.80MUSDFY2025 · Dec 31, 2025Interest Paid
25.07MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-198.97MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.76MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
1.59MUSDFY2025 · Dec 31, 2025Stock-based Compensation
17.68MUSDFY2025 · Dec 31, 2025Other Non-cash Items
39.66MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.60MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.67MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
-439.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-658.38MUSDFY2025 · Dec 31, 2025Sale of Investments
337.19MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-321.62MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
391.90MUSDFY2025 · Dec 31, 2025Shares Outstanding
69.33MSharesUpdated Sep 28, 2026Float Shares
57.52MSharesUpdated Sep 28, 2026Shares Short
9.92MSharesUpdated Sep 28, 2026Short Ratio
8.62daysvs all stocks
Short % of Shares Outstanding
14.49%vs all stocks
% Held by Insiders
1.26%vs all stocks
% Held by Institutions
97.96%vs all stocks
Total Cash (MRQ)
810.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
11.68USDUpdated Sep 28, 2026Total Debt (MRQ)
552.17MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.70xvs Biotechnology peers
Current Ratio (MRQ)
10.01xvs Biotechnology peers
Book Value per Share (MRQ)
4.67USDUpdated Sep 28, 2026Total Assets
824.91MUSDvs all stocks (USD)
Total Current Assets
655.99MUSDFY2025 · Dec 31, 2025Total Liabilities
626.01MUSDFY2025 · Dec 31, 2025Total Non-current Assets
168.92MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
563.09MUSDFY2025 · Dec 31, 2025Total Current Liabilities
62.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
80.24MUSDFY2025 · Dec 31, 2025Other Short-term Investments
542.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
5.86MUSDFY2025 · Dec 31, 2025Accounts Payable
5.17MUSDFY2025 · Dec 31, 2025Short-term Debt
3.86MUSDFY2025 · Dec 31, 2025Other Current Liabilities
23.46MUSDFY2025 · Dec 31, 2025Long-term Debt
59.53MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
495.59MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.69MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.33BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
198.90MUSDvs all stocks (USD)
52-Week Low
8.73USDUpdated Sep 28, 202652-Week High
71.50USDUpdated Sep 28, 202652-Week Change
-35.64%vs all stocks
Beta
0.9440xvs all stocks
50-Day MA
44.49USDUpdated Sep 28, 2026200-Day MA
29.55USDUpdated Sep 28, 2026Avg 10-Day Volume
1.48MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.27MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-4.06USDUpdated Sep 28, 2026Other Income / Expense
39.51MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 810,334,976Total Debt (USD): 552,166,976Debt-to-Equity: 1.70
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 10.01Altman Z-Score: 0.64
Financial Health
Altman Z-Score 0.64: distress zoneCritical
Altman Z-Score: 0.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $18.67M, lower than 95% of all stocks globallySignificant
Revenue (USD): 18,672,000Global P5: 33,357,653.812
Market cap is $2.65B, above the global median of $1.18BNotable
Market cap (USD): 2,651,877,930Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
NewAmsterdam Pharma Co. N.V.
Tier 1ProductionApproval-Gated PipelineRule
Yili Chuanning Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axogen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heron Neutron Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Precigen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Slac Precision Equipment Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hunan Huasheng Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wanbangde Pharmaceutical Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated